On August 27th, according to market reports, Sanofi has decided to temporarily suspend the supply and sales of influenza vaccines in China due to efficacy issues. In response to this, a reporter from Nancai News called Sanofi, and the customer service staff responded, "There is currently no definite news, and we need to wait for the official response." Flu vaccine concept stocks in the secondary market also experienced changes, with Hualan Vaccine (301207. SZ) and Jindike (688670) both hitting the daily limit up of 20CM in the morning. The reporter called Hualan Vaccine as an investor, and relevant personnel stated that there is no potency issue with the company's influenza vaccine. If Sanofi withdraws from the supply, there will be no products from the company during this year's vaccination season, which is a good thing for other competing manufacturers. As for how much specific share each company can receive, it cannot be predicted.